1. MITO 27
Randomized Phase II study on Pembrolizumab plus chemotherapy versus chemotherapy alone in recurrent, platinum-resistant ovarian cancer (a MITO Group Study)

2. Study design Random1.1 MITO 27 N= 138
II line chemotherapy
(physician choice):
- PLD 40 mg/mq d1 q28;
- Weekly Paclitaxel 80 mg/mq d1,8,15 q28
Gemcitabine 1000 mg/mq gg1,8,15 q28
N= 138 R A N D O M I Z T
- Recurrent, platinum resistant (no refractory) epithelial ovarian, Fallopian tube, primary Peritoneal cancer
- No more than 2 previous CHT lines
- Evaluable or Measurable disease
II line chemotherapy
(physician choice):
- PLD 40 mg/mq d1 q28;
- Weekly Paclitaxel 80 mg/mq d1,8,15 q28
Gemcitabine 1000 mg/mq gg1,8,15 q28
+ Pembrolizumab 200 mg every 3 weeks flat dose
Random1.1
MITO 27

3. Study design
Safety:
The phase 1 studies on the combination of pembro with Weekly paclitaxel and gemcitabine have been already published
The phase 1 study on the combination of Pembro with PLD is ongoing (Matulonis)
MITO 27

4. Objectives Primary: Secondary: Overall survival (OS)
The combination of pembrolizumab and chemotherapy is expected to increase overall survival with respect to chemotherapy alone
Secondary:
- Progression-free survival (PFS)
- Toxicity
- Response rate
- QoL
Correlation between PD1-PDL1 as evaluated in
immuno- istochemistry and Pembrolizumab response
MITO 27

5. Inclusion Criteria MITO 27
Platinum resistant (platinum free interval 1-6 months from last platinum dose) ovarian, Fallopian tube or primary peritoneal cancer;
Be willing and able to provide written informed consent/assent for the trial;
Be  18 years of age on day of signing informed consent;
Have measurable disease or evaluable based on RECIST 1.1 (patients with only CA 125 increase without evidence of disease are not included);
Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion. Newly-obtained is defined as a specimen obtained up to 6 weeks (42 days) prior to initiation of treatment on Day 1. Subjects for whom newly-obtained samples cannot be provided (e.g. inaccessible or subject safety concern) may submit an archived specimen;
Have a performance status of 0 or 1 on the ECOG Performance Scale;
Demonstrate adequate organ function as defined in Table 1, all screening labs should be performed within 10 days of treatment initiation;
Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required;
Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication (Reference Section 6.5.2). Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.
MITO 27

6. Exclusion Criteria – Part 1
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
Has received >2 previous CHT lines
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
Has a known history of active TB (Bacillus Tuberculosis)
Hypersensitivity to pembrolizumab or any of its excipients.
Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent.
Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may qualify for the study.
Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
MITO 27

7. Exclusion Criteria – Part 2
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability;
Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
Has an history of, or any actual evidence of active, non-infectious pneumonitis that required steroids treatment
Has an active infection requiring systemic therapy.
Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject’s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
Is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
Patients should not be breast-feeding during treatment and for 120 days following the end of treatment
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
Has received a live vaccine within 30 days of planned start of study therapy.
MITO 27

8. Statistical consideration
This is a phase II randomized multicenter trial, aiming at evaluating activity of Pembrolizumab in combination to chemotherapy versus chemotherapy alone in recurrent, platinum resistant ovarian cancer.
Approximately 138 patients will be randomized in a 1:1 ratio to chemotherapy or chemotherapy-Pembrolizumab combination to ensure a sample size comprising 98 events (69 evaluable patients per treatment arm).
The trial will provide 80% power to detect a significant improvement in the primary endpoint (median OS) for the addition of pembrolizumab to chemotherapy from 13 months to 20 months (HR 0.65, one tail alpha level of 0.1%).
46 patients will be enrolled in each cohort (weekly paclitaxel, gemcitabine, pegylated liposomal doxorubicin). With a possible accrual rate of 6 patients/month, 138 patients will be enrolled in about 24 months.
MITO 27

9. Administrative Information
Academic trial
NCI of Milan sponsor
Data center: NCI of Milan (MITO center)
Planned study start: October 2017
Assurance and Pembrolizumab provided
Merck support: Pembrolizumab and financial support for data management,
insurance and drug management
10-15 Italian sites
To participate please contact:
MITO 27